ADC Bio received a new development grant from the Welsh government for its new antibody drug conjugate manufacturing technology that it hopes will make drug production cheaper. The new "lock and release" method will minimize production steps and cut costs.
The new technology is performed on a solid support versus current methods done in solution at high dilution. Binding the antibody to a solid support prior to the conjugation step provides some of the following advantages according to ADC Bio:
- column binding of the antibody followed by conjugation to the cytoxic drug allows all superfluous reactants to be washed away from the immobilized antibody
- structural integrity of the antibody binding activity is maintained
- the antibody is protected throughout the process and can't be lost by leakage providing signficant risk management for pricey material
- reportedly production yields are increased in the new process by minimizing antibody aggregation
ADC Bio expects to begin testing commercial scale production in the next year and a half. It plans to license the technology to CMOs and drug companies. The prospect of ADC's making a much bigger splash in cancer therapeutics over the next decade bodes well for demand for ADC manufacturing services and technologies.
Posted by Bruce Lehr Dec 13th 2011.